Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherBASIC SCIENCE INVESTIGATIONS

Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases

Greg M. Thurber, Stefan C. Zajic and K. Dane Wittrup
Journal of Nuclear Medicine June 2007, 48 (6) 995-999; DOI: https://doi.org/10.2967/jnumed.106.037069
Greg M. Thurber
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan C. Zajic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Dane Wittrup
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

Targeting tumors with antibody-based therapeutics is a complex task presenting multiple kinetic barriers. Antibody internalization and clearance inhibit uptake both in solid tumors, limited by tumor vascular permeability, and in micrometastases, limited by diffusion. Methods: A modeling exercise is used to introduce 2 simple criteria that must be less than unity for saturation of both tumors and micrometastases. The clearance modulus and the Thiele modulus are ratios of the plasma clearance rate and antibody catabolism, respectively, to the tumor tissue penetration rate. Results: Even low rates of antigen internalization from constitutive membrane turnover can significantly retard antibody penetration. Rapid clearance of single-chain variable fragments also hinders uptake, often more than counterbalancing their more rapid extravasation and diffusion. Conclusion: The model illustrates that with the large resistance from the tumor capillary, antibodies may be more suitable for targeting micrometastases than vascularized tumors.

  • molecular imaging
  • monoclonal antibodies
  • radionuclide therapy
  • biodistribution
  • penetration
  • pharmacokinetics

Antibodies and antibody fragments are promising agents for cancer detection and treatment. One of the major restrictions of these drugs for cancer therapy is poor transport, which results in low concentrations and a lack of targeting of all cells in a tumor (1). Delivery of antibodies to tumor cells is a complex task with many rates involved, as illustrated in Figure 1. Effective therapy requires treatment of both solid, vascularized tumors and micrometastases with different pharmacokinetic parameters.

FIGURE 1. 
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1. 

Rate processes for tumor and micrometastasis targeting include blood clearance (1), extravasation (2), lymphatic clearance in normal tissue (3), diffusion into tumor tissue (4), binding (5), internalization (6), recycling (7), and degradation (8). The spheric (metastasis) and cylindric (tumor) radii (R) are similar because of oxygen diffusion and consumption limitations but may differ slightly.

Several different models have been developed to illustrate some fundamental trends in targeting. van Osdol et al. have shown that antibodies tend to exhibit a “binding site barrier” because of their clearance and penetration (2), and extensive work on fluid flow and macromolecular distribution has been performed by Jain (1). Using a simplified model, Graff and Wittrup highlighted the importance of antibody dose for saturating tissue and the necessity of high affinity for retention in the tumor (3).

Although providing useful insights, these prior models have not fully delineated the microscopic distribution effects of antibody catabolism. The turnover rate was not examined quantitatively, and one would expect differences between an antibody binding a receptor internalized by a clathrin-coated pit mechanism, constitutive membrane turnover, and extracellular matrix protein turnover. Internalization of ErbB receptor family members, targets for 2 antibody drugs approved by the Food and Drug Administration, is well characterized (4,5). A multitude of other antibodies against various targets have also been shown to internalize at broadly varying rates (6,7), demonstrating the need for an in-depth consideration of the effects of internalization on tumor targeting. This analysis reveals that internalization has the potential to severely limit the penetration of antibodies.

MATERIALS AND METHODS

We present 2 criteria to predict the extent of antibody targeting before and during saturation. The model is validated against published experimental data and is intended to provide a framework in which to analyze and interpret antibody targeting in vivo while also highlighting strategies for improvement in antibody micropharmacokinetics.

Dimensionless ratios of pairs of critical rates, sometimes referred to as moduli, simplify identification of the most dominant rates under particular conditions. We derive here 2 such moduli for tumor targeting.

Clearance Modulus

The clearance modulus, Γ, is a ratio of the time to saturate a given volume of tissue to the time that the antibody persists in the plasma. If the characteristic time for targeting a given radius is longer than the time the antibody is in the blood ( Math), antibody will not reach this distance.MathEq. 1MathEq. 2The R2 term defines the volume of tissue considered in a Krogh-like cylinder or spheric metastasis, [Ag]t is the antigen concentration in the overall tumor volume, and Math is the effective void fraction. [Ab]plasma,0 is the initial plasma concentration of a bolus dose. P is the permeability of the tumor vascular wall (8), and Rcap is the radius of the capillary vessel. The remaining terms are the weighted average of the biexponential decay in the plasma. κ and λ are the normal capillary permeability and lymphatic drainage constants, respectively.

Thiele Modulus

The Thiele modulus captures the rate of antibody catabolism in the tumor compared with the time required to saturate the tissue by diffusion. If the characteristic time for internalization and catabolism is faster than the time required for antibody to reach the most distant tumor tissue (Math), antibody will be degraded before it completely saturates the tumor.MathEq. 3whereMathEq. 4MathEq. 5where the normal tissue concentration isMathEq. 6for a constant infusion and is set to the plasma concentration for bolus doses. The internalization rate constant ke represents the rate of catabolism in the tumor tissue, and [Ag] represents the concentration of internalizing antigen. Bi is the mass transfer Biot number, a dimensionless number characterizing transport resistances in series. For a small Biot number, permeability dominates over diffusion.

These parameters together define necessary conditions for tumor saturation:Math

Failure of either criterion is sufficient for failure to saturate the tumor volume. In addition to providing criteria for saturation of a given tumor volume, Math and Γtumor enable prediction of the depth of penetration of bound antibody. One of these parameters will approximately equal 1 at the distance of maximum antibody penetration, because by definition that is the point at which the diffusion or extravasation rate is balanced by either systemic clearance or antibody catabolism as illustrated in Figure 2.

FIGURE 2. 
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2. 

Antibody penetration distance limited by clearance (A and B) or antigen turnover (C and D). Pharmacokinetic parameters are from Table 1; antigen concentration is 0.1 μM. Formulas for R are located in the supplemental data (available online only at http://jnm.snmjournals.org).

RESULTS

For experimental validation (Fig. 3), 2 datasets that were not compounded by clearance effects were chosen to verify the Thiele modulus. Independent estimates for the various parameters were obtained from the literature (Tables 1 and 2). In the first experiment (10), single-chain variable fragments (scFvs) were dosed in anephric mice, eliminating rapid renal clearance. Before kidney removal, the clearance modulus of 3.8 indicates poor targeting due to the rapid drop in plasma concentration. In the second (11), continuous dosing of a slow-clearing antibody kept the effective concentration high throughout the experiment. Caution must be taken when interpreting other targeting results of tumors with high catabolism rates using radioactive tracers. Additional factors, such as the residualizing or nonresidualizing nature of the radioisotope, must also be taken into consideration (12). Also, for very low doses of radioactive antibodies used in diagnostics, more targeting may occur near the periphery of the tumor where there is some convection due to fluid leakage. By improving the moduli and saturating a larger fraction of the tumor, the imaging signal will be improved. However, this must be carefully weighed against any increased background from larger doses or longer clearance times.

FIGURE 3. 
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3. 

Experimental validation. (A) Model prediction (top); image adapted from Adams et al. (9), with yellow fluorescence marking capillary, red fluorescence indicating antibody, and green circle indicating model-predicted distance for penetration without any fitted parameters (kon = 7 × 105 M−1s−1; other parameters are in Table 1) (center); and fluorescence vs. distance using ImageJ (bottom). (B) Tumor size as fraction of control vs. Thiele modulus (with trastuzumab), defined using 100-μm distance, which corresponds with targeting 95% of tumor tissue (9). (C) Growth attenuation vs. fraction of tumor that is predicted to be saturated by model. The distances given in Baish et al. (9) were used.

View this table:
  • View inline
  • View popup
TABLE 1

Previously Published Parameter Values Used in Simulations

View this table:
  • View inline
  • View popup
TABLE 2

Clearance Parameters for Various Antibodies and Fragments

The 2 criteria for effective targeting are not independent. In many cases, both clearance and internalization occur on similar time scales. To address the interaction between the two, full numeric simulations were performed with both internalization and clearance (Fig. 4).

FIGURE 4. 
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4. 

Full numeric simulations were performed with biexponential clearance and catabolism in tumor tissue. Antibody concentration was varied to change clearance modulus, and endocytosis rate was varied to independently change Thiele modulus. met = metastasis.

DISCUSSION

The moduli provide insight into improving targeting. Increases in antibody dose unambiguously improve both Math and Math with capillary permeability necessitating large doses for solid tumors. Practical concerns, such as toxicity, immunogenicity, and economics, set an upper limit to this parameter. Extending the plasma half-life minimizes Math for agents such as scFvs, which clear too quickly to target all cells. A more rapid diffusivity helps targeting in micrometastases, and this is most easily achieved by smaller molecules, often trading off with faster clearance. To increase penetration into the tumor, Math should be minimized by using “noninternalizing” antibodies, such as antibodies that are effectively recycled in the endosome, extracellular matrix proteins, shed antigen, trapped necrotic debris, or perhaps tight-junction antigens. However, drugs requiring antibody uptake (e.g., immunotoxins and chemotherapeutic conjugates) clearly cannot apply this strategy; the particular problems with immunotoxin uptake versus diffusion have been quantitatively considered previously (13). Antigen level plays a subtle role in trading off pharmacodynamics vs. micropharmacokinetics. High expression levels provide a large amount of target, but this can limit penetration into the tumor. Although ideal for imaging, therapeutic targeting can be significantly hindered by these levels. Once Math is high enough to enable delivery of a cell-killing dose of drug to an individual cell, any further increases only serve to worsen the distribution of drug throughout the tumor because of proportional increases in ϕ2 and Math. For highly potent cytotoxic payloads such as α-particle–emitting radionuclides that kill cells with delivery of only 1–10 molecules of drug, antigens with 105–106 molecules per cell present an unnecessarily onerous impediment to diffusion through the tumor tissue. Capillary permeability provides a very large barrier for solid tumor uptake as illustrated by the small Biot number. Attempts to improve P in solid tumors through transcytosis by caveolar targeting have begun to meet with initial success in this regard (14). Even in these scenarios, it may not be possible to effectively target larger tumors with significant necrotic areas lacking functional blood vessels or even vascularized tumors less than the roughly 1-cm detection limit, which are slightly less heterogeneous. Finally, the distance Math from the circulating source of antibody drug will in general be smaller for micrometastases relative to vascularized bulk tumors, supporting a strategy of applying antibody therapeutics primarily to adjuvant therapy for minimal residual disease after resection (15).

CONCLUSION

Scaling arguments such as those presented in this paper can be useful analytic tools for qualitative consideration of overall systems behavior when multiple different rate phenomena are present (e.g., clearance, binding, endocytosis, diffusion). Arguably, the ability to generalize such simplistic analyses is actually preferable to detailed descriptive models of specific cases, when one is considering highly variable phenomena such as tumor physiology. The scaling analysis indicates that even low levels of antigen turnover can severely limit penetration of antibodies into tumor tissue; clearance of antibodies, especially fragments that are rapidly filtered, restricts penetration; and the large resistance of the tumor capillary wall may make antibodies more suitable for targeting micrometastases than solid tumors.

Acknowledgments

Funding was provided by CA101830 and CA96504 and by a NIGMS/MIT Biotechnology Training Grant to one of the authors. Thanks are due to Matthew Lazzara for a detailed critical reading of the mathematic derivations and to Mike Schmidt for particularly helpful discussions of the significance of clearance versus penetration and antigen downregulation.

Footnotes

  • COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

References

  1. 1.↵
    Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng. 1999;01:241–263.
    OpenUrlCrossRef
  2. 2.↵
    van Osdol W, Fujimori K, Weinstein J. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a “binding site barrier.” Cancer Res. 1991;51:4776–4784.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Graff C, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003;63:1288–1296.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Austin C, Maziere A, Pisacane P, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 2004;15:5268–5282.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Baulida J, Kraus MH, Alimandi M, DiFiore PP, Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem. 1996;271:5251–5257.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Kyriakos R, Shih L, Ong G, Patel K, Goldenberg D, Mattes MJ. The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res. 1992;52:835–842.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Mattes MJ, Griffiths G, Diril H, Goldenberg D, Ong G, Shih L. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer. 1994;73:787–793.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Gerlowski L, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res. 1986;31:288–305.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Baish J, Gazit Y, Berk D, Nozue M, Baxter L, Jain RK. Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc Res. 1996;51:327–346.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Adams G, Schier R, McCall A, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61:4750–4755.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin (TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58:2825–2831.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Press OW, Shan D, Howell Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123–2129.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Wenning LA, Murphy RM. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Biotechnol Bioeng. 1999;62:562–575.
    OpenUrlCrossRefPubMed
  14. 14.↵
    McIntosh D, Tan X, Oh P, Schnitzer J. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci U S A. 2002;99:1996–2001.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Koppe MJ, Bleichrodt RP, Oyen WJG, Boerman OC. Radioimmunotherapy and colorectal cancer. Br J Surg. 2005;92:264–276.
    OpenUrlCrossRefPubMed
  • Received for publication October 10, 2006.
  • Accepted for publication November 27, 2006.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 48 (6)
Journal of Nuclear Medicine
Vol. 48, Issue 6
June 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases
Greg M. Thurber, Stefan C. Zajic, K. Dane Wittrup
Journal of Nuclear Medicine Jun 2007, 48 (6) 995-999; DOI: 10.2967/jnumed.106.037069

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases
Greg M. Thurber, Stefan C. Zajic, K. Dane Wittrup
Journal of Nuclear Medicine Jun 2007, 48 (6) 995-999; DOI: 10.2967/jnumed.106.037069
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • In vivo Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity Antibodies
  • Mechanistically Weighted Metric to Predict In Vivo Antibody-Receptor Occupancy: An Analytical Approach
  • Strategies to enhance monoclonal antibody uptake and distribution in solid tumors
  • Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy
  • Increased Tumor Penetration of Single-Domain Antibody-Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models
  • Effect of Size on Solid Tumor Disposition of Protein Therapeutics
  • Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
  • Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors
  • Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival
  • Improved Modeling of In Vivo Kinetics of Slowly Diffusing Radiotracers for Tumor Imaging
  • Effect of Small-Molecule-Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody
  • Reactive polymer enables efficient in vivo bioorthogonal chemistry
  • Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors
  • TCR Mimic Monoclonal Antibody Targets a Specific Peptide/HLA Class I Complex and Significantly Impedes Tumor Growth In Vivo Using Breast Cancer Models
  • Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis
  • A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
  • Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry
  • Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids
  • Quantitative Spatiotemporal Analysis of Antibody Fragment Diffusion and Endocytic Consumption in Tumor Spheroids
  • Google Scholar

More in this TOC Section

  • How Sensitive Is the Upper Gastrointestinal Tract to 90Y Radioembolization? A Histologic and Dosimetric Analysis in a Porcine Model
  • 11C-Methionine PET of Myocardial Inflammation in a Rat Model of Experimental Autoimmune Myocarditis
  • Counting Rate Characteristics and Image Distortion in Preclinical PET Imaging During Radiopharmaceutical Therapy
Show more Basic Science Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire